Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

• DOI: 10.1126/science.abc5902
• Publication Date: 2020-06-15T23:15:17Z
• Authors: Philip J. M. Brouwer; Tom G. Caniels; Karlijn van der S...; Jonne L. Snitselaar; Yoann Aldon; Sandhya Bangaru; Jonathan L. Torres; Nisreen M. A. Okba; Mathieu Claireaux; Gius Kerster; Arthur E. H. Bent...; Marlies M. van Ha...; Denise Guerra; Judith A. Burger; Edith E. Schermer; Kirsten D. Verheul; Niels van der Velde; Alex van der Kooi; Jelle van Schooten; Mariëlle J. van B...; Tom P. L. Bijl; Kwinten Sliepen; Aafke Aartse; Ronald Derking; Ilja Bontjer; Neeltje A. Kootstra; W. Joost Wiersinga; Gestur Vidarsson; Bart L. Haagmans; Andrew B. Ward; Godelieve J. de Bree; Rogier W. Sanders; Marit J. van Gils
• Keywords: 2019-20 coronavirus outbreak; Vulnerability; Betacoronavirus; Coronavirus Infections

Sites of vulnerability in SARS-CoV-2 Antibodies that neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be an important tool treating disease 2019 (COVID-19). Brouwer et al. isolated 403 monoclonal antibodies from three convalescent COVID-19 patients. They show the patients had strong immune responses against viral spike protein, a complex binds to receptors on host cell. A subset was able virus. Competition and electron microscopy studies showed these target diverse epitopes spike, with two most potent targeting domain receptor. Science , this issue p. 643